Abstract
A post-marketing clinical trial was carried out in ambulatory patients to assess the efficacy and toleration of atenolol (100 mg)/chlorthalidone (25 mg) tablets in the treatment of arterial hypertension. Data are reported on a cut-off at 2449 patients. Analysis of results in the different age groups has shown that after 4 weeks of treatment there was a mean fall of 16–17% in systolic and of 16–18% in diastolic blood pressure. Adequate blood pressure reduction was obtained for all age groups. The frequency of adverse reactions/events was low, these being reported in only 5·7% of cases. As discontinuation of treatment on account of adverse reactions/events occurred in 3·8% of patients, the risk-to-benefit relationship of atenolol/chlorthalidone tablets was very favourable.
Get full access to this article
View all access options for this article.